v3.26.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2026
Dec. 31, 2025
Current assets    
Cash and cash equivalents $ 12,634 $ 10,278
Prepaid expenses and other current assets 433 597
Total current assets 13,067 10,875
Property and equipment, net 8 17
Right-of-use asset 175 210
Other assets 21 21
Total assets 13,271 11,123
Current liabilities    
Accounts payable 921 1,060
Clinical trial accrued liabilities 2,825 79
Accrued expenses and other current liabilities 606 993
Warrant liabilities 23 136
Related party payable $ 1,897 $ 3,312
Other Liability, Current, Related Party [Extensible Enumeration] Related Party [Member] Related Party [Member]
Lease liability, short-term $ 74 $ 68
Total current liabilities 6,346 5,648
Lease liability, long-term 103 142
Total liabilities 6,449 5,790
Commitments and contingencies (Note 6)
Stockholders' equity    
Preferred stock, $0.001 par value per share; 10,000,000 shares authorized and no shares issued or outstanding as of June 30, 2026 and December 31, 2025
Common stock, $0.001 par value per share, 100,000,000 shares authorized as of June 30, 2026 and December 31, 2025; 6,575,656 and 2,308,294 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively 7 2
Additional paid-in capital 164,784 154,161
Accumulated deficit (157,969) (148,830)
Total stockholders' equity 6,822 5,333
Total liabilities and stockholders' equity $ 13,271 $ 11,123